Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Corticosteroid
|
| gptkbp:approvedBy |
1961
|
| gptkbp:ATCCode |
gptkb:H02AB02
|
| gptkbp:brand |
gptkb:Ozurdex
gptkb:Decadron gptkb:Maxidex |
| gptkbp:CASNumber |
gptkb:50-02-2
|
| gptkbp:contraindication |
Systemic fungal infection
|
| gptkbp:discoveredBy |
gptkb:Philip_Showalter_Hench
|
| gptkbp:drugClass |
gptkb:Corticosteroid
|
| gptkbp:eliminationHalfLife |
36-54 hours
|
| gptkbp:excretion |
Urine
|
| gptkbp:hasMolecularFormula |
C22H29FO5
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dexamethasone
|
| gptkbp:IUPACName |
(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
|
| gptkbp:legalStatus |
Prescription only
|
| gptkbp:mechanismOfAction |
Binds to glucocorticoid receptor
Suppresses immune response Suppresses inflammation |
| gptkbp:metabolism |
Liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
5743
5540 |
| gptkbp:routeOfAdministration |
gptkb:Oral
Intramuscular Intravenous Inhalation Topical Ophthalmic |
| gptkbp:sideEffect |
gptkb:Insomnia
Weight gain Hypertension Hyperglycemia Osteoporosis Mood changes Increased appetite Increased risk of infection |
| gptkbp:UNII |
7S5I7G3JQL
|
| gptkbp:usedFor |
Immunosuppression
Anti-inflammatory Treatment of COVID-19 Treatment of asthma Treatment of cerebral edema Treatment of certain cancers Treatment of croup Treatment of severe allergies |
| gptkbp:WHOModelListOfEssentialMedicines |
Yes
|
| gptkbp:bfsParent |
gptkb:Antiemetics
gptkb:50-02-2 gptkb:Corticosteroid |
| gptkbp:bfsLayer |
6
|